Similar articles

Abstract: Objective: The aim of this study was to evaluate the concentrations of C-reactive protein (CRP), tumor necrosis factor-α; (TNF-α;), interleukin-6 (IL-6), and the degree of homeostasis model assessment-insulin resistance (HOMA-IR) in patients with morbid obesity exposed to a three-week low-calorie diet and balneotherapy. Methods: The study included 33 patients (25 females and 8 males; mean age 46 years) with body mass index (BMI) values of >40 kg/m². Evaluations of CRP, IL-6, TNF-α, lipid profile, HOMA-IR, and fasting glucose were carried out before (baseline data) and three weeks after the treatment. The control group consisted of 20 healthy volunteers (15 females and 5 males) with a mean age of 39 years and BMI values of ≤24.9 kg/m². Results: In the blood of patients with morbid obesity we found significantly elevated levels of CRP, TNF-α, triglycerides, HOMA-IR and fasting glucose, but a decreased level of high density lipoprotein (HDL)-cholesterol, compared with the healthy individuals. The treatment resulted in about a 9.4% reduction in body weight from 122.5 to 111.0 kg and a significant decrease in the concentration of CRP, but no change in TNF-α or IL-6. HOMA-IR was significantly reduced. Conclusions: The decrease in CRP level without changes in TNF-α or IL-6 concentrations after the low-calorie diet and balneological treatment, suggests that an essential amount of adipose tissue must be removed before proper adipocyte function is restored. The decrease in HOMA-IR indicates an improvement in insulin sensitivity, which is beneficial in obese patients.

病态肥胖患者在接受治疗体重减少后C反应蛋白、肿瘤坏死因子α和白细胞介素-6的水平变化

[1]Bataille, R., Klein, B., 1992. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum., 35(8):982-984.

[2]Cardillo, S., Seshadri, P., Iqbal, N., 2006. The effects of a low-carbohydrate versus low-fat diet on adipocyto-kines in severely obese adults: three-year follow-up of a randomized trial. Eur. Rev. Med. Pharmacol. Sci., 10:99-106.

[3]Clifton, P.M., 2003. Diet and C-reactive protein. Curr. Atheroscler. Rep., 5(6):431-436.

[4]Cottam, D.R., Mattar, S.G., Barinas-Mitchel, E., et al., 2004. The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: implications and effects of weight loss. Obes. Surg., 14(5):589-600.

[5]Czyżewska, J., Wasilewska, K., Kamińska, J., et al., 2012. Assess the impact of concentrations of inflammatory markers: IL-6, CRP in the presence of albuminuria in patients with type 2 diabetes. Pol. Merk. Lek., 32(188):98-102 (in Polish).

[6]Drenick, E.J., Bale, G.S., Seltzer, F., et al., 1980. Excessive mortality and causes of death in morbidly obese men. JAMA, 243(5):443-445.

[7]Gabay, C., 2006. Interleukin-6 and chronic inflammation. Arthritis. Res. Ther., 8(Suppl. 2):S3.

[8]Goyal, R., Faizy, A.F., Siddiqui, S.S., et al., 2012. Evaluation of TNF-α and IL-6 levels in obese and non-obese diabetics: pre- and postinsulin effects. N. Am. J. Med. Sci., 4(4):180-184.

[9]Gregor, M.F., Hotamisligil, G.S., 2011. Inflammatory mechanisms in obesity. Annu. Rev. Immunol., 29(1):415-445.

[10]Gutenbrunner, C., Bender, T., Cantista, P., et al., 2010. A proposal for a worldwide definition of health resort medicine, balneology, medical hydrology and climatology. Int. J. Biometeorol., 54(5):495-507.

[11]Hanh, T., Serog, P., Fauconnier, J., et al., 2012. One-year effectiveness of a 3-week balneotherapy program for the treatment of overweight or obesity. Evid. Based Complement. Alternat. Med., 2012:150839.

[12]Hofso, D., Ueland, T., Hager, H., et al., 2009. Inflammatory mediators in morbidly obese subjects: associations with glucose abnormalities and changes after oral glucose. Eur. J. Endocrinol., 161(3):451-458.

[13]Jarosz, M., Grodowska, A., 2008. Obesity treatment. Fam. Med. Prim. Care Rev., 10(4):1361-1366 (in Polish).

[14]Johansson, K., Neovius, M., Hemmingsson, E., 2014. Effects of anti-obesity drugs, diet, and exercise on weight-loss maintenance after a very-low-calorie diet or low-calorie diet: a systematic review and meta-analysis of randomized controlled trials. Am. J. Clin. Nutr., 99(1):14-23.

[15]Oláh, M., Koncz, Á., Fehér, J., et al., 2011. The effect of balneo-therapy on antioxidant, inflammatory, and metabolic indices in patients with cardiovascular risk factors (hypertension and obesity)—a randomised, controlled, follow-up study. Contemp. Clin. Trials, 32(6):793-801.

[16]Olszanecka-Glinianowicz, M., Chudek, J., Kocełak, P., et al., 2011. Body fat changes and activity of tumor necrosis factor α system—a 5-year follow-up study. Metabolism, 60(4):531-536.

[17]Solá, E., Jover, A., López-Ruiz, A., et al., 2009. Parameters of inflammation in morbid obesity: lack of effect of moderate weight loss. Obes. Surg., 19(5):571-576.

[18]Switzer, N., Mangat, H., Karmali, S., 2013. Current trends in obesity: body composition assessment, weight regulation, and emerging techniques in managing severe obesity. J. Interv. Gastroenterol., 3(1):34-36.

[19]Szymocha, M., Bryła, M., Maniecka-Bryła, I., 2009. The epidemic of obesity in the 21st century. Zdr. Publ., 119:207-212 (in Polish).

[20]van Dielen, F.M.H, van't Veer, C., Schols, A.M., et al., 2001. Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals. Int. J. Obes. Relat. Metab. Disord., 25(12):1759-1766.

[21]Vázquez, L.A., Pazos, F., Berrazueta, J.R., et al., 2005. Effects of changes in body weight and insulin resistance on inflammation and endothelial function in morbid obesity after bariatric surgery. J. Clin. Endocrinol. Metab., 90(1):316-322.

[22]Verma, S., Szmitko, P.E., Yeh, E.T.H., 2004. C-reactive protein. Circulation, 109(16):1914-1917.

[23]Visser, M., Bouter, L.M., McQuillan, G.M., et al., 1999. Elevated C–reactive protein levels in overweight and obese adults. JAMA, 282(22):2131-2135.

[24]Xydakis, A.M., Case, C.C., Jones, P.H., et al., 2004. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J. Clin. Endocrinol. Metab., 89(6):2697-2703.

[25]Zahorska-Markiewicz, B., Janowska, J., Olszanecka-Glinianowicz, M., et al., 2000. Serum concen-trations of TNF-α and soluble TNF-α receptors in obesity. Int. J. Obes. Relat. Metab. Disord., 24(11):1392-1395.

[26]Zahorska-Markiewicz, B., Olszanecka-Glinianowicz, M., Janowska, J., et al., 2008. The effect of weight loss on serum concentrations of FAS and tumour necrosis factor α in obese women. Endokrynol. Pol., 59:19-22 (in Polish).